CYTK 250516 60.00C(CYTK250516C60000) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

Clear

All

Quotes

News

Learn

Help

All

News

Announcements

No matches yet

Operations too frequent. Please try again later.

Please check network settings and try again Refresh Refresh

History record

CYTK250516C60000

Watchlist

0.06
-0.10-62.50%

15min DelayTrading May 2 14:19 ET

0.10High0.06Low

Intraday

5D
Daily

News

Cytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK
BusinesswireMay 2 11:45 ET
Cytokinetics Analyst Ratings
BenzingaMay 2 08:23 ET · Ratings
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session
BenzingaMay 2 08:04 ET
BofA Securities Maintains Cytokinetics(CYTK.US) With Hold Rating, Cuts Target Price to $50
Moomoo NewsMay 2 07:31 ET · Ratings
Needham Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $72
Moomoo NewsMay 2 07:31 ET · Ratings
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Moomoo NewsMay 2 07:31 ET · Ratings

Comments

Teddy123

Mar 20 19:46

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

$Cytokinetics (CYTK.US)$
Groundbreaking Healthcare Tool Unlocks Insights from 65,000 Pharmacies' HCM Data

Narga101

Feb 21 07:35

hidden gem right here

$Cytokinetics (CYTK.US)$

Movers and Shakers

Dec 24, 2024 21:57

Columns Today's Pre-Market Movers and Top Ratings | TIVC, NEUE, X, and More

Morning Movers
Gapping up
$Tivic Health Systems (TIVC.US)$ shares jumped 76% in Tuesday premarket after CEO Jennifer Ernst announced plans for 2025 cash flow initiatives and disease-specific clinical trials for regulatory approvals.
$NeueHealth (NEUE.US)$ stock surged 62% after announcing its agreement to be acquired and taken private by a New Enterprise Associates affiliate in a deal valued at approximately $1.3 billion.
$SEALSQ Corp (LAES.US)$ shares c...

Sean Parker

Nov 19, 2024 16:56

$Cytokinetics (CYTK.US)$
Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and ...

Mr Long Term

Aug 14, 2024 06:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...